Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status

Min Zhang, H. Yang, D'Arcy Holman

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)

Abstract

Epidemiological and experimental studies suggest that isoflavones may protect against breast cancer by acting as estrogen agonists or antagonists. A case-control study was conducted in southeast China in 2004–2005 to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor (ER) and progesterone receptor (PR) status. The incident cases were 756 female patients with histologically confirmed breast cancer. The 1,009 age-matched controls were healthy women randomly recruited from outpatient breast clinics. We assessed isoflavone intake by face-to-face interview using a validated and reliable food-frequency questionnaire and obtained tumor ER and PR status from pathologic reports. Compared with women in the lowest intake quartiles, those in the highest quartile of total isoflavone intake had a reduced risk of all receptor status subtypes of breast cancer with a dose-response relationship. The adjusted ORs (95% CIs) were 0.39 (0.27–0.58) for ER+, 0.32 (0.21–0.49) for ER−, 0.43 (0.29–0.64) for PR+, and 0.30 (0.19–0.45) for PR− (P for trend
Original languageEnglish
Pages (from-to)553-563
JournalBreast Cancer Research and Treatment
Volume118
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status'. Together they form a unique fingerprint.

Cite this